Biology Reference
In-Depth Information
TABLE 12.2 Nucleotide Excision Repair as a Predictive Marker in Human CancersdCont'd
Cancer type
Treatment
Repair enzyme
Results
Reference
Gastro-
Esophageal
Cisplatin-based
ERCC1
Nuclear expression associated with
poor histological response.
147
DFS and
Y
OS
Ovary
Platinum-based
ERCC1
High mRNA level associated with
platinum resistance
148, 149
Bladder
Cisplatin-based
ERCC1
High gene expression associated with
poor overall PFS
154
Prostate
RT
ERCC1
N118N (500C
T) polymorphism not
associated with survival
117
>
Nasopharynx
RT
ERCC1
High protein score associated with
153
Y
locoregional recurrence. No
association distant failure-free or OS
Cervix
RT
ERCC1
Low mRNA expression associated
with
150
Y
OS
Cervix
Platinum-based
ERCC1
Low expression associated with longer
DFS and better response to Cx
151
Breast
Cisplatin/paclitaxel
ERCC1
Expression level not associated with
response to Cx or OS
152
Gastric
CRT plus surgery
ERCC2
Lys/lys genotype codon 751 associated
with
162
[
incidence of relapse
CRC
Oxaliplatin/5FU
ERCC2
RR and median survival in Lys/lys
genotype codon 751 homozygotes
163
[
CRC
Irinotecan-based
ERCC2
Codon 752 allelic variants not
associated with outcome or grade 3 or
4 hematological or gastrointestinal
toxicity
109
NSCLC
Platinum-based
ERCC2
No association between Lys751Gln
polymorphism and survival
105
NSCLC
Platinum-based
ERCC2
No association between Lys751Gln
polymorphism and RR
164
NSCLC
Platinum-based
ERCC2
No association between Aps312Asn
polymorphism and treatment response
128
NSCLC
Platinum-based
ERCC2
Variant (Asn) genotype codon 312
associated with
103
OS
Y
NSCLC
Cisplatin/gemcitabine
ERCC2
Trend towards better response with
codon 312 polymorphism
165
NSCLC
Platinum-based
ERCC2
Meta-analysis
e
no association
between Asp312Asn and Lys751Gln
polymorphism and response to
treatment
134
NSCLC
Platinum-based
ERCC2
Meta-analysis
e
no association
between PFS or OS
135
Bladder
Platinum-based
ERCC2
Combined genotypes with
1 variant
allele in ERCC2 or XRCC1 associated
with
167
cancer-specific survival
[
AML
Cx
ERCC2
Lys/Lys polymorphisms of Lys751Gln
associated with
168
DFS and OS
[
MM
Autologous BMT
ERCC2
Carriers Lys751Gln associated with
169
[
time to treatment failure
